Patents by Inventor Lena Edelman

Lena Edelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Screening methods for the identification of inhibitors of human immunodeficiency virus (HIV) viral protein R (Vpr) binding to the adenine nucleotide translocator (ANT)
    Patent number: 7642051
    Abstract: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: January 5, 2010
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite de Technologie de Compiegne
    Inventors: Etienne Daniel Francois Jacotot, Guido Kroemer, Bernard Pierre Roques, Lena Edelman, Johan Hoebeke, Catherine Brenner-Jean, Anne-Sophie Belzacq
  • Mimetics and inhibitors of the interaction between Vpr (HIV viral protein of regulation) and ANT (Mitochondrial adenine nucleotide translocator)
    Patent number: 7056735
    Abstract: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: June 6, 2006
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite de Technologie de Compiegne
    Inventors: Etienne Daniel Francois Jacotot, Guido Kroemer, Bernard Pierre Roques, Lena Edelman, Johan Hoebeke, Catherine Brenner-Jean, Anne-Sophie Belzacq
  • Mechanism of mitochondrial membrane permeabilization by HIV-1 VPR, mimetics of Vpr and methods of screening active molecules having the ability to alter and/or prevent and/or mimic the interaction of Vpr with ANT
    Publication number: 20060052285
    Abstract: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
    Type: Application
    Filed: July 8, 2005
    Publication date: March 9, 2006
    Applicants: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite de Technologie de Compiegne
    Inventors: Etienne Jacotot, Guido Kroemer, Bernard Roques, Lena Edelman, Johan Hoebeke, Catherine Brenner-Jean, Anne-Sophie Belzacq
  • Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
    Publication number: 20040265300
    Abstract: A chimeric polypeptide has the formula: pTox-pTarg, wherein pTox is a viral apoptotic peptide, such as the Vpr peptide of HIV-1 or a fragment of the Vpr peptide of HIV-1 containing the amino acid motif H(F/S)RIG that interacts with mitochondrial inner membrane, adenine nucleotide translocation (ANT) protein of a cell. pTarg is an antibody or an antibody fragment that binds to the outer membrane of the cell. Binding of the chimeric polypeptide to the cell is followed by apoptosis of the cell. A vector encoding a chimeric polypeptide and a recombinant host cell comprising the vector are provided. The chimeric polypeptide us useful for targeting pTox to cells, such as cancer cells.
    Type: Application
    Filed: July 28, 2003
    Publication date: December 30, 2004
    Inventors: Lena Edelman, Etienne Daniel Francois Jacotot, Jean-Paul Briand
  • Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
    Publication number: 20030077826
    Abstract: A chimeric polypeptide has the formula: pTox-pTarg, wherein pTox is a viral apoptotic peptide, such as the Vpr peptide of HIV-1 or a fragment of the Vpr peptide of HIV-1 containing the amino acid motif H(F/S)RIG that interacts with mitochondrial inner membrane, adenine nucleotide translocation (ANT) protein of a cell. pTarg is an antibody or an antibody fragment that binds to the outer membrane of the cell. Binding of the chimeric polypeptide to the cell is followed by apoptosis of the cell. A vector encoding a chimeric polypeptide and a recombinant host cell comprising the vector are provided. The chimeric polypeptide is useful for targeting pTox to cells, such as cancer cells.
    Type: Application
    Filed: January 31, 2002
    Publication date: April 24, 2003
    Inventors: Lena Edelman, Etienne Daniel Francois Jacotot, Jean-Paul Briand
  • Mimetics and inhibitors of the interaction between Vpr (HIV vIral protein of regulation) and ANT (mitochondrial adenine nucleotide translocator)
    Publication number: 20020068273
    Abstract: The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
    Type: Application
    Filed: September 12, 2001
    Publication date: June 6, 2002
    Inventors: Etienne Daniel Francois Jacotot, Guido Kroemer, Bernard Pierre Roques, Lena Edelman, Johan Hoebeke, Catherine Brenner-Jan, Anne-Sophie Belzacq
  • Monoclonal recombinant anti-rhesus D (D7C2) antibody
    Patent number: 6312690
    Abstract: Cloning of DNA fragments which code for the light chain or the heavy chain variable domain of the D7C2 monoclonal antibody within a baculovirus. The invention also concerns the expression of these DNA fragments in insect host cells, the anti-rhesus D recombinant monoclonal antibody so obtained and its use.
    Type: Grant
    Filed: July 1, 1997
    Date of Patent: November 6, 2001
    Assignees: Institut Pasteur, Proteine Performance
    Inventors: Léna Edelman, Christel Margaritte, Michel Kaczorek, Hassan Chaabihi